Loading
SSGJ-706 is an experimental bispecific antibody from Shenyang Sunshine Pharmaceutical in phase 2 trials for non-small-cell lung cancer, aimed at PD-1 and PD-L1.
SSGJ-706 is a bispecific antibody developed by Shenyang Sunshine Pharmaceutical. Its targets are PD-1 and PD-L1. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT07171606, plans to enrol 240 participants with primary completion was scheduled for 2026-08-31 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
1.One arm of SSGJ-706 binds PD-1 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"SSGJ-706" OR ABSTRACT:"SSGJ-706") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SSGJ-706, not a curated reading list.
Shares PD-L1, PD-1, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1, PD-1, Non-small-cell lung cancer and the tag pipeline.
Shares 3SBio and the tag pipeline.
Shares PD-L1, Non-small-cell lung cancer and the tag pipeline.
Shares 3SBio and the tag pipeline.
Shares 3SBio and the tag pipeline.